Haemato AG
HAEK | F
Overview
Corporate Details
- ISIN(s):
- DE000A289VV1
- LEI:
- 529900Q3CGRYVCW7E340
- Country:
- Germany
- Address:
- Lilienthalstraße 3a, 12529 Schönefeld
- Website:
- https://haemato.de/en/start.html
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Haemato AG is a pharmaceutical company that functions as a manufacturer and wholesaler of specialty pharmaceuticals. The company's core business is focused on high-priced therapies for chronic diseases within five main therapeutic areas: HIV/AIDS, neurology, oncology, rheumatology, and ophthalmology. Its portfolio includes innovative patent-protected medicines, biosimilars, generics, and narcotics, including cannabis products, which it supplies to pharmacies, wholesalers, and clinics. Additionally, Haemato AG operates in the Lifestyle & Aesthetics sector, where it develops, manufactures, and distributes its own brands, such as M1 SELECT cosmetics and diagnostic tests, alongside supplying third-party products.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Haemato AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-04-10 00:00 |
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 314.8 KB | |
| 2025-01-15 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
|
German | 30.6 KB | |
| 2024-09-26 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 56.0 KB | |
| 2024-02-09 00:00 |
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
|
German | 343.3 KB | |
| 2023-12-12 00:00 |
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
|
German | 61.5 KB | |
| 2023-11-30 14:14 |
Delisting Announcement
HAEMATO AG: Termination of listing in the Open Market
|
English | 8.7 KB | |
| 2023-11-16 08:21 |
Earnings Release
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase o…
|
English | 15.5 KB | |
| 2023-11-15 19:42 |
Regulatory News Service
Termination of the botulinum toxin project
|
English | 8.1 KB | |
| 2023-10-30 00:00 |
Interim Report
Half-yearly financial statements 2023
|
English | 1.8 MB | |
| 2023-10-30 00:00 |
Interim Report
Half-yearly financial statements 2023
|
English | 1.8 MB | |
| 2023-08-31 09:00 |
Earnings Release
HAEMATO AG publishes figures for the first half of 2023
|
English | 9.7 KB | |
| 2023-06-09 00:00 |
Annual Report
Annual financial statements 2022
|
English | 5.9 MB | |
| 2023-06-09 00:00 |
Annual Report
Annual financial statements 2022
|
English | 5.9 MB | |
| 2023-05-31 16:34 |
Earnings Release
HAEMATO AG with a strong start into the year 2023: Revenue increase of over 2…
|
English | 8.6 KB | |
| 2023-05-16 17:40 |
Notice of Dividend Amount
HAEMATO AG: Dividend of EUR 1.20
|
English | 5.7 KB |
Automate Your Workflow. Get a real-time feed of all Haemato AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Haemato AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
